Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns “Buy” Rating from D. Boral Capital

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $2.00 price objective on the stock. D. Boral Capital’s target price would indicate a potential upside of 14.29% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Monday. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, Lineage Cell Therapeutics presently has an average rating of “Buy” and an average target price of $4.25.

Lineage Cell Therapeutics Trading Up 0.6%

Shares of Lineage Cell Therapeutics stock opened at $1.75 on Tuesday. The company has a 50-day moving average of $1.71 and a two-hundred day moving average of $1.22. Lineage Cell Therapeutics has a 12-month low of $0.37 and a 12-month high of $2.09. The stock has a market cap of $399.63 million, a PE ratio of -9.72 and a beta of 1.77.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.11). Lineage Cell Therapeutics had a negative return on equity of 20.00% and a negative net margin of 374.84%.The firm had revenue of $3.68 million for the quarter, compared to analysts’ expectations of $2.30 million. On average, sell-side analysts forecast that Lineage Cell Therapeutics will post -0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several hedge funds have recently modified their holdings of LCTX. Broadwood Capital Inc. grew its holdings in shares of Lineage Cell Therapeutics by 18.9% during the first quarter. Broadwood Capital Inc. now owns 49,560,992 shares of the company’s stock worth $22,382,000 after buying an additional 7,894,737 shares in the last quarter. Vanguard Group Inc. boosted its position in Lineage Cell Therapeutics by 6.2% during the third quarter. Vanguard Group Inc. now owns 9,006,930 shares of the company’s stock worth $15,222,000 after acquiring an additional 524,057 shares during the last quarter. Defender Capital LLC. boosted its position in Lineage Cell Therapeutics by 7.5% during the second quarter. Defender Capital LLC. now owns 6,785,177 shares of the company’s stock worth $6,157,000 after acquiring an additional 474,304 shares during the last quarter. Comerica Bank grew its stake in Lineage Cell Therapeutics by 275.0% in the 1st quarter. Comerica Bank now owns 3,000,000 shares of the company’s stock worth $1,355,000 after acquiring an additional 2,200,000 shares during the period. Finally, Millennium Management LLC raised its holdings in Lineage Cell Therapeutics by 3.1% in the 3rd quarter. Millennium Management LLC now owns 2,680,003 shares of the company’s stock valued at $4,529,000 after acquiring an additional 79,426 shares during the last quarter. 62.47% of the stock is owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.